Peptide LocalCompare price, evidence & access
Search /Compare vendors
Home/Peptide database
Evidence-linked peptide database

Peptide database.
Status, evidence, prices.

Search 40 peptide records and 139 aliases across FDA-approved medicines, drugs in clinical trials, and US research peptide price boards. Every result includes a current status, checked date, category boundary, and primary source.

New to the category? Start with “What are peptides?” →
Looking for benefits, risks, cost, or a provider? Open the peptide therapy field manual →

ByPeptide Local Editorial DeskUpdated July 17, 2026How we review
40published entity records
139searchable aliases and codes
12research, medicine, and pipeline families
211evidence references across profiles
Peptide evidence navigator

Choose a name. Ask one clear question.

Get the status, FDA boundary, linked clinical trials, evidence coverage, price-comparison route, country map, or next comparison for any published record. Every answer keeps approved medicines, clinical programs, and research seller data separate.

2. Choose your question
FDA-approved medicineChecked July 18, 2026

Direct answer

What is the current status of WEGOVY (Semaglutide)?

WEGOVY (Semaglutide) is filed here as an FDA-approved medicine record. The current record is NDA 215256 · FDA-approved prescription drug, from Novo Nordisk Inc., with injection and tablets · subcutaneous and oral. Approval belongs to this exact product and label record.
This category can answer
Which exact product, application, label company, route, and regulatory record did FDA approve?
It cannot establish
Approval applies to the exact medicine and label record. It does not transfer to compounded products, research listings, or similarly named materials, and it does not determine individual suitability.

This tool routes evidence; it does not diagnose, prescribe, rank clinical benefit, or certify a seller. Record count is coverage, not an evidence-strength score.

The status map

One index does not mean one comparison.

Research listings, approved medicines, and clinical development answer different questions. The database makes all three discoverable while keeping their evidence, schema, and commercial boundaries separate.

Lane 0120 records

Research market boards

Exact-size public seller observations with list price, availability, document access, shipping language, and a checked date.

Answers
What did public US research catalogs show?
Does not answer
Clinical safety, approval, dose, or treatment suitability.
Browse price comparisons →
Lane 027 records

Approved medicine records

Exact brand, active ingredient, FDA application, labeled use, presentation, and current DailyMed record for regulated prescription products.

Answers
Which exact product and label did FDA approve?
Does not answer
Individual suitability, a treatment choice, or equivalence to compounded or research products.
Browse approved medicines →
Lane 0313 records

Clinical pipeline profiles

Sponsor, registry, trial, phase, mechanism, result, and regulatory records for investigational obesity and metabolic programs.

Answers
What has been studied and what is the current development record?
Does not answer
Approval, launch date, individual benefit, or online-vial legitimacy.
Browse clinical pipeline →
Category checkpoint≠

Same name does not mean same product, route, evidence, or legal status.

Open safety map ↗
Search the published record

One name search. Three evidence lanes.

Search exact names, former names, sponsor codes, aliases, families, mechanisms, or routes. A result opens the correct market, medicine, or clinical record; the lanes never merge.

2records shown
01Clinical pipeline profile

CagriSema

cagrilintide + semaglutide · REDEFINE 1 · REIMAGINE 1-3

Family
Obesity and metabolic pipeline
Sponsor
Novo Nordisk
Current record
Phase 3 / US regulatory review
Coverage
8 cited records

Amylin analogue + GLP-1 receptor agonist · Once-weekly subcutaneous injection

02FDA-approved medicine

WEGOVY (Semaglutide)

semaglutide · Wegovy · NDA 215256 · GLP-1 receptor agonist · semaglutide injection · semaglutide tablets · oral Wegovy · Wegovy pill · sémaglutide · semaglutida · Semaglutid · 司美格鲁肽

Family
FDA-approved incretin medicine
Label company
Novo Nordisk Inc.
Current record
NDA 215256 · FDA-approved prescription drug
Coverage
7 primary regulatory records

Injection and tablets · Subcutaneous and oral

Worldwide, province, and state maps

41 names across 42 countries, 10 Canadian provinces, and 50 US states.

Each map resolves the compound identity first, then connects it to localized country answers, official Canadian province routes, or US state pharmacy records without merging evidence categories.

Identity resolution

The searches most likely to cross a category line.

These name clusters are kept visible because aliases, sponsor codes, combinations, and approved-product names can send readers to the wrong evidence record.

03Cagrilintide · CagriSema

One component is not the fixed-dose combination.

Cagrilintide has its own investigational program. CagriSema combines cagrilintide with semaglutide and therefore has a separate evidence record, trial program, and regulatory path.

Open cagrilintide profile Open CagriSema profile
04Amycretin · zenagamtide · NNC0487-0111

A development name can change while the evidence trail continues.

The pipeline profile keeps the former name, current nonproprietary name, and sponsor code together so older trial coverage resolves to the same dated program record.

Open zenagamtide / amycretin profile
05MariTide · maridebart cafraglutide · AMG 133

Brand-like shorthand, generic name, and sponsor code can point together.

All three names route to one investigational profile, where monthly evidence, quarterly-maintenance evidence, Phase 3 status, and unresolved claims stay attached to their sources.

Open MariTide profile
Peptide database FAQ

Direct answers to the questions behind the search.

These answers define what the database can verify, where the category changes, and which record to open next.

01

What is in the Peptide Local peptide database?

The database contains 40 source-linked records in three separate categories: 7 exact FDA-approved medicine records, 13 investigational clinical programs, and 20 dated US research-market price boards. It also resolves 139 alternate names, sponsor codes, application numbers, and common search terms.

02

Which peptides are FDA approved?

FDA approval belongs to an exact medicine, application, label, dosage form, route, and approved use. Use the approved-medicine lane to verify records such as WEGOVY, ZEPBOUND, SAXENDA, VYLEESI, SCENESSE, EGRIFTA WR, and FOUNDAYO. A similar ingredient name, compounded product, or research vial does not inherit that approval.

03

Is retatrutide FDA approved?

No. Retatrutide is tracked as an investigational Eli Lilly clinical program, not an FDA-approved retail medicine. Its profile links the current development phase, mechanism, trial records, reported findings, checked date, and unresolved questions without converting clinical research into a launch or approval claim.

04

Can I compare research peptide prices?

Yes, when the compound name, nominal size, seller market, visible list price, availability signal, and checked date match. Peptide Local currently maintains 20 exact-size research price boards. Price and seller-document access still do not prove identity, purity, quantity, sterility, safety, legality, or suitability for use.

05

Where can I buy peptides?

Start by identifying the category. An FDA-approved medicine requires the appropriate prescription and a licensed pharmacy route. A research-market listing is not a treatment-shopping substitute and should be assessed through exact seller identity, destination rules, current stock, landed cost, lot documentation, and source dates. Peptide Local compares public claims but does not certify a seller as safe.

06

How do I check a peptide in another country?

Resolve the exact ingredient, medicine, or clinical program first, then check the destination country's official product database and its separate pharmacy, seller, establishment, or supply records. A US approval, clinical status, or research listing does not transfer worldwide. The database links every covered name to a 42-country verification map.

Coverage rule

Published evidence, not an endless peptide-name dump.

This database currently includes every qualified Peptide Local price board, every published approved-medicine record, and every maintained pipeline profile. An entity is added only when it has a substantive internal record, a dated evidence trail, searchable aliases, and a category-safe destination.

Absence from the database does not establish that a substance is safe, unsafe, legal, illegal, approved, or unapproved. It means Peptide Local has not yet published a record that clears the relevant evidence gate.

Check a peptide by destination country →Download the open peptide evidence and status index →Download the 1722-row global country dataset →Download the 2050-row US state dataset →Download the 410-row Canada province dataset →Download the 328-row Australia jurisdiction dataset →Read the publication gates →Audit the source registry →